Applies to Medicaid plans.
Covered (preferred drug)Qualification pathways
You can qualify through any one of these.
Initial approval for Type 2 Diabetes (Preferred Agent)
All of:
- Patient is ≥ 18 years of age
- Diagnosis of type 2 diabetes mellitus
- HbA1c ≥ 6.5% measured within the past 6 months (documentation required)
- Trial and failure of metformin within the past 2 years, unless contraindicated or patient is intolerant (documentation required)
Documentation to bring
- HbA1c lab result ≥ 6.5% within the past 6 months
- Documentation of metformin trial and failure within the past 2 years, OR documentation of contraindication or intolerance to metformin
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- Renewal: Improvement in A1C.
- Renewal: Documentation of improved clinical response (e.g., decline in HbA1c); patient has not experienced any treatment-restricting adverse effects; dosing is appropriate per labeling or supported by compendia. Initial BMI, metformin trial, and preferred agent step therapy are not re-verified at continuation.
Policy note: Ozempic is listed as a preferred agent requiring Clinical Prior Authorization. The metformin trial lookback window is 2 years. A1C lookback window is 6 months. Non-preferred agents (Rybelsus) require an additional step of trial and failure/adverse reaction/contraindication to preferred GLP-1s. Rybelsus (oral semaglutide) is a non-preferred agent in this policy; though it contains semaglutide, it does not meet the in-scope brand criteria for a separate criteria entry as it is not Ozempic or Wegovy.
Policy effective June 16, 2025 · verified June 4, 2026 · source: Glucagon Like%20 Peptide 1%20(GLP-1)%20 Receptor%20 Agonist%20and%20 Related%20 Agents%2003.12.2026